The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Willis, Andrew ^a   Rivers, Peter ^b   Gray, Laura J ^a   Davies, Melanie ^a   Khunti, Kamlesh ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PHARMACY; PRIMARY MEDICAL CARE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; DEMOGRAPHY; GENERAL PRACTITIONER; MASS SCREENING; PREVALENCE; PUBLISHING;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GENERAL PRACTITIONERS; HUMANS; MASS SCREENING; PHARMACIES; PREVALENCE; PUBLICATION BIAS; REFERRAL AND CONSULTATION; RESIDENCE CHARACTERISTICS; RISK FACTORS;

EID: 84898920888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091157     Document Type: Article

References (39)

1. May A, Kuklina E, Yoon P (2012) Prevalence of Cardiovascular Disease Risk Factors among US adolescents, 1999-2008 Pediatrics 129: 1035-1041.
2. International Diabetes Foundation (2011) Diabetes Atlas Fifth Edition.
3. Zhang P, Zhang X, Brown B, Vistisen D, Sicree R, et al. (2011) Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87: 293-301.
4. World Health Organisation (2011) Global atlas on cardiovascular disease prevention and control.
5. Chatterjee R, Narayan K, Lipscomb J, Phillips L (2010) Screening Adults for Pre-Diabetes and Diabetes May Be Cost Saving. Diabetes care 33: 1484-1490.
6. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, SJ G (2010) Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. British Medical Journal 23.
7. Buijsse B, Simmons RK, Griffin SJ, Schulze MB (2011) Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 Diabetes. Epidemiologic Reviews 33: 46-62.
8. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, et al. (2010) Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabetic Medicine 27: 995-1003.
9. Teh R, Chen T, Krass I (2001) Consumer perspectives of pharmacist delivered health promotion and screening services. Int J Pharm Pract 9: 261-267. (Pubitemid 34038328)
10. McElnay J, Nicholl A, Grainger-Rousseau T (1993) The role of community pharmacist - a survey of public opinion in N Ireland. Int J Pharm Pract 2: 95-100.
11. Blenkinsopp A, Anderson C, Armstrong M (2003) Systematic Review of the effectivness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. Journal of Public Health Medicine 25: 144-153. (Pubitemid 36758777)
12. Anderson C (2000) Health promotion in community pharmacy: the UK situation. Patient Education and Councelling 39: 285-291.
13. Hunt BD, Hiles SL, Chauhan A, Ighofose C, Bharakhada N, et al. (2013) Evaluation of the Healthy LifeCheck programme: a vascular risk assessment service for community pharmacies in Leicester city, UK. Journal of Public Health 35: 440-446.
14. Popham F (2011) To what extent can deprivation inequalities in mortality and heart disease incidence amongst the working aged in Scotland be explained by smoking? Relative and absolute approaches. Health & place 17: 1132-1136.
15. Agency for Healthcare Research and Quality US Preventive Services Task Force Evidence Syntheses formerly Systematic Evidence Reviews (2009) U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville: (MD).
16. Olenak JL, Calpin M (2010) Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome. Journal of the American Pharmacists Association: JAPhA 50: 32-36.
17. Mangum SA, Kraenow KR, Narducci WA (2003) Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. Journal of the American Pharmaceutical Association (Washington, DC: 1996). 43 (1): 50-55.
18. Hutchison JC (1979) Hypertension detection and compliance: permanent site hypertensive evaluation-a new method of increasing patient compliance. Angiology 30: 568-576.
19. Madejski RM, Madejski TJ (1996) Cholesterol screening in a community pharmacy. Journal of the American Pharmaceutical Association (Washington, DC: 1996). NS36 (4): 243-248.
20. Krass I, Mitchell B, Clarke P, Brillant M, Dienaar R, et al. (2007) Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Research & Clinical Practice 75: 339-347. (Pubitemid 46074203)
21. Gardner SF, Skelton DR, Rollins SD, Hastings JK (1995) Community pharmacy data bases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy 15 (3): 292-296.
22. Pongwecharak J, Treeranurat T (2010) Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharmacy World and Science 32 (3): 329-333.
23. Peterson GM, Fitzmaurice KD, Kruup H, Jackson SL, Rasiah RL (2010) Cardiovascular risk screening program in Australian community pharmacies. Pharmacy World and Science 32 (3): 373-380.
24. Karwalajtys T, Kaczorowski J, Hutchison B, Myers MG, Sullivan SM, et al. (2009) Blood pressure variability and prevalence of hypertension using automated readings from multiple visits to a pharmacy-based community-wide programme. Journal of Human Hypertension 23: 585-589.
25. Jafari M, Masih M, Emerson JF (2001) The value of pharmacist involvement in a point-of-care service, walk-in lipid screening program. Pharmacotherapy 21 (11): 1403-1406.
26. Hourihan F, Krass I, Chen T (2003) Rural community pharmacy: A feasible site for a health promotion and screening service for cardiovascular risk factors. Australian Journal of Rural Health 11 (1): 28-35. (Pubitemid 37038451)
27. Horgan JMP, Blenkinsopp A, McManus RJ (2010) Evaluation of a cardiovascular disease opportunistic risk assessment pilot ('Heart MOT' service) in community pharmacies. Journal of Public Health 32 (1): 110-116.
28. Hersberger KE, Botomino A, Mancini M, Bruppacher R (2006) Sequential screening for diabetes - Evaluation of a campaign in Swiss community pharmacies. Pharmacy World and Science 28 (3): 171-179. (Pubitemid 44584052)
29. Earle KA, Taylor P, Wyatt S, Burnett S, Ray J (2001) A physician-pharmacist model for the surveillance of blood pressure in the community: A feasibility study. Journal of Human Hypertension 15 (8): 529-533. (Pubitemid 32780644)
30. Edwards C (1981) Blood pressure measurement by pharmacists. Journal of the Royal College of General Practitioners 31: 674-676.
31. Donyai P, Van Den Berg M (2009) Coronary heart disease risk screening: The community pharmacy Healthy Heart Assessment Service. Pharmacy World and Science 31 (6): 643-647.
32. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283: 2008-2012. (Pubitemid 30214957)
33. Edwards A, Evans R, Dundon J, Haigh S, Hood K, et al. (2006) Personalised risk communication for informed decision making about taking screening tests. Cochrane Database of Systematic Reviews.
34. National Health and Medical Research Council (2009) National Evidence Based Guideline for Case Detection and Diagnosis of Type 2 Diabetes.
35. Colagiuri S (2012) The cost of screening for diabetes and intermediate hyperglycaemia Diabetes Research and Clinical Practice Online
36. Office for National Statistics (2011) Health Survey for England.
37. Wang C, McPhearson K, Marsh T, Gortmaker S, Brown M (2011) Health and Economic burden of the projected obesity trends in the USA and the UK. Lancet 378: 815-825.
38. Cutler J, Sorlie P, Wolz M, Thom T, Fields L, et al. (2008) Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988-1994 and 1999-2004. Hypertension 52: 818-827.
39. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31-40.